Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients
Barclays Maintains Equal-Weight on Anteris Technologies Glb, Lowers Price Target to $9
Anteris Technologies advances PARADIGM trial and manufacturing scale-up in third quarter
Anteris Technologies Announces Results for the Third Quarter of 2026
Anteris Technologies reports strong 30-day DurAVR heart valve outcomes from EMBARK Study
Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026
Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
Anteris Technologies To Present First 30-Day Clinical And Hemodynamic Outcomes For Its Medium-Size DurAVR Transcatheter Heart Valve At The Transcatheter Cardiovascular Therapeutics Conference, October 31-November 3
Anteris Technologies secures German clearance to expand PARADIGM heart valve trial
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
Cantor Fitzgerald Reiterates Overweight on Anteris Technologies Glb, Maintains $15 Price Target
Barclays Initiates Coverage On Anteris Technologies Glb with Equal-Weight Rating, Announces Price Target of $10
Anteris Technologies appoints Brent Moen as chief financial officer
Anteris to Present at September Healthcare Investor Conferences
Reported Earlier, Anteris Technologies Glb Q2 EPS $(0.30) Misses $(0.21) Estimate, Sales $1.009M Miss $1.500M Estimate
Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway
Anteris Technologies Announces Results for the Second Quarter of 2026
TAVR Changed Valve Replacement; Anteris Says Longer-Living Patients Expose the Next Challenge
France clearance marks key milestone for Anteris' pivotal PARADIGM Trial
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.